With no unexpected signals, a recent review of tralokinumab safety out to 1 year found no unexpected signals and provided some information about potential advantages of flexible dosing.
Final results from a phase 3 trial with the investigational DCVax-L vaccine show that overall survival was increased both in patients with newly diagnosed glioblastoma as well as recurrent disease.
Experts have identified shortcomings in a study that suggests that surgical masks are not inferior to N95 masks for protecting healthcare workers against COVID-19.
A personalized intervention that focused on known Alzheimer s risk factors showed "modest" improvement at 2 years that was greater than a control intervention, new results from the SMAART study show.